Press release
Global GM2 Gangliosidosis Clinical Trials 2025: Drug Pipeline, Regulatory Approvals, and Market Growth Analysis by DelveInsight
DelveInsight's "GM2 Gangliosidosis - Pipeline Insight, 2025" delivers an in-depth evaluation of the global research and development landscape, profiling both clinical and preclinical drug candidates with varied mechanisms of action. The report explores key advancements including AAV-based gene therapies focused on the central nervous system, innovations in delivery technologies, and novel approaches aimed at improving long-term safety and efficacy. It also examines shifting regulatory frameworks, biomarker-guided clinical trial designs, and strategic collaborations that are driving accelerated therapy development for this challenging disease.Given the significant clinical and scientific hurdles posed by GM2 gangliosidosis, the growing therapeutic pipeline presents promising opportunities to revolutionize treatment strategies and enhance outcomes for this underserved patient population.
Want to explore the latest treatment landscape and major factors influencing the GM2 gangliosidosis pipeline? Visit: https://www.delveinsight.com/report-store/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The therapeutic landscape for GM2 gangliosidosis-a rare inherited lysosomal storage disorder that includes Tay-Sachs and Sandhoff diseases-is experiencing increasing innovation, with the development pipeline focusing on disease-modifying and potentially curative treatments. GM2 gangliosidosis results from mutations in the β-hexosaminidase A and/or B enzymes, causing harmful accumulation of GM2 gangliosides in neurons and leading to progressive neurodegeneration. Despite the disease's severity, current treatment options are mostly supportive, underscoring a critical unmet need for effective therapies.
Biopharmaceutical firms and academic institutions are advancing diverse novel strategies such as gene therapies, enzyme replacement therapies, substrate reduction therapies, and pharmacological chaperones. Companies like Sanofi, Sio Gene Therapies, IntraBio Inc., Taysha Gene Therapies, and JCR Pharmaceuticals are at the forefront, developing experimental candidates aimed at restoring enzyme function or decreasing the buildup of toxic substrates.
Key Highlights from the GM2 Gangliosidosis Pipeline Report
• DelveInsight's analysis reveals a dynamic GM2 gangliosidosis pipeline with over 8 active companies developing more than 8 investigational therapies targeting this rare disorder.
• Prominent players in the GM2 gangliosidosis space include Sanofi, Sio Gene Therapies, IntraBio Inc., Taysha Gene Therapies, JCR Pharmaceuticals, Azafaros B.V., Allievex Corp., Recursion, Polaryx, among others, all advancing their leading drug candidates to enhance treatment options.
• Notable pipeline therapies under development at various stages include Venglustat, AXO-AAV-GM2, IB1001, TSHA-101, JR-479, AZ-3102, AX 451, PLX-300, and additional candidates.
• In July 2025, Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses.
• In January 2025, Azafaros B.V. announced that its lead compound, nizubaglustat, received orphan drug designation from both the U.S. FDA and the European Union for GM1 gangliosidosis. The company's Clinical Trial Application (CTA) for two global Phase 3 studies evaluating the drug's efficacy in GM1/GM2 gangliosidoses and Niemann-Pick Type C (NPC) was approved by multiple European regulators, with trials scheduled to commence in Q2 2025.
Request a sample to explore the latest advancements in the GM2 gangliosidosis pipeline landscape at https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
GM2 Gangliosidosis Overview:
GM2 Gangliosidosis is a group of rare, inherited lysosomal storage disorders that primarily include Tay-Sachs disease and Sandhoff disease. These conditions result from genetic mutations affecting the enzymes β-hexosaminidase A and/or B, which are essential for breaking down GM2 gangliosides-a type of fatty substance-in nerve cells. When these enzymes are deficient or dysfunctional, GM2 gangliosides accumulate excessively within neurons, leading to progressive neurodegeneration.
The disease typically manifests in infancy or early childhood with symptoms such as muscle weakness, loss of motor skills, vision and hearing impairment, seizures, and cognitive decline. As the disorder progresses, affected individuals experience severe neurological deterioration, often resulting in premature death.
Currently, treatment options for GM2 Gangliosidosis are limited and largely supportive, focusing on symptom management and improving quality of life. There are no approved disease-modifying therapies yet, which emphasizes the urgent need for novel treatments.
Ongoing research is exploring various therapeutic approaches, including gene therapy, enzyme replacement, substrate reduction therapy, and pharmacological chaperones, aimed at addressing the underlying enzyme deficiencies. Despite the challenges posed by the disease's rarity and complexity, advances in biotechnology and genetic medicine offer hope for more effective and potentially curative treatments in the future.
Find out more about GM2 gangliosidosis medication at https://www.delveinsight.com/report-store/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
GM2 Gangliosidosis Treatment Overview: Drug Profiles
Venglustat - Sanofi
Venglustat is an oral inhibitor of glucosylceramide synthase (GCS), an enzyme responsible for converting ceramide into glucosylceramide (GL-1) during lipid metabolism. GL-1 subsequently forms globosides like Gb3, which accumulate in diseases such as Fabry disease due to α-galactosidase A deficiency. By blocking GCS, venglustat lowers GL-1 levels, helping to prevent Gb3 buildup. Currently, venglustat is undergoing Phase III clinical trials for the treatment of GM2 gangliosidoses.
AXO-AAV-GM2 - Sio Gene Therapies
AXO-AAV-GM2 is an investigational gene therapy targeting GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases-severe, inherited pediatric neurodegenerative disorders caused by mutations in the HEXA or HEXB genes. These mutations result in deficient β-hexosaminidase A (HexA) enzyme activity, causing progressive neurodegeneration. The therapy delivers functional copies of both genes using two co-administered AAVrh8 viral vectors to restore HexA function. AXO-AAV-GM2 has received FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations. It is currently the only gene therapy in development for all pediatric forms of GM2 gangliosidosis. In 2018, Sio acquired global rights from UMass Chan Medical School for developing and commercializing gene therapies for GM1 and GM2 gangliosidoses.
Discover the latest innovative and emerging therapies in the GM2 gangliosidosis pipeline at https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
GM2 Gangliosidosis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Explore comprehensive insights on therapies for GM2 gangliosidosis treatment at: https://www.delveinsight.com/sample-request/gm2-gangliosidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the GM2 Gangliosidosis Pipeline Report
• Coverage: Global
• Key GM2 Gangliosidosis Companies: Sanofi, Sio Gene Therapies, IntraBio Inc., Taysha Gene Therapies, JCR Pharmaceuticals, Azafaros B.V., Allievex Corp., Recursion, Polaryx, and others.
• Key GM2 Gangliosidosis Pipeline Therapies: Venglustat, AXO-AAV-GM2, IB1001, TSHA-101, JR-479, AZ-3102, AX 451, PLX-300, and others.
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global GM2 Gangliosidosis Clinical Trials 2025: Drug Pipeline, Regulatory Approvals, and Market Growth Analysis by DelveInsight here
News-ID: 4142860 • Views: …
More Releases from DelveInsight Business Research
Vitiligo Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA App …
The "Vitiligo Pipeline Insight, 2025" report by DelveInsight delivers an in-depth view of the current clinical development scenario along with the future growth trajectory of the Vitiligo Market.
As per DelveInsight's evaluation, the global Vitiligo treatment pipeline features 20+ leading companies actively engaged in developing 20+ therapeutic candidates. The analysis covers Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and developmental updates.
The Vitiligo Pipeline report offers extensive commercial and clinical…
Myelodysplastic Syndrome Competitive Landscape 2025: Clinical Trial Analysis, Th …
DelveInsight's, "Myelodysplastic Syndrome Pipeline Insight 2025" report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
• DelveInsight's Myelodysplastic Syndrome…
Fibromyalgia Competitive Landscape 2025: Clinical Trial Analysis, Therapies, FDA …
According to DelveInsight, the global Fibromyalgia pipeline features more than eight key companies actively developing over ten treatment candidates. The analysis encompasses ongoing clinical trials, therapeutic mechanisms of action, routes of administration, and recent developments within the Fibromyalgia treatment landscape.
The Fibromyalgia Pipeline 2025 report provides an exhaustive evaluation of pipeline products, ranging from preclinical stages to marketed therapies. It includes comprehensive details on each drug's mechanism of action, clinical trial…
Chronic Wounds Competitive Landscape 2025: Clinical Trial Analysis, Therapies, F …
As per DelveInsight's assessment, globally, Chronic Wounds pipeline constitutes 7+ key companies continuously working towards developing 8+ Chronic Wounds treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Wounds Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Wounds Market.
The Chronic Wounds Pipeline report embraces in-depth commercial and clinical assessment…
More Releases for GM2
GM2 Gangliosidosis Market to Witness Promising Upswing by 2034, DelveInsight For …
DelveInsight's "GM2 Gangliosidosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the GM2 Gangliosidosis, historical and forecasted epidemiology as well as the GM2 Gangliosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
GM2 Gangliosidosis Market Outlook, Trends, Therapies and Growth Forecast
GM2 gangliosidosis is a group of rare, inherited lysosomal storage disorders caused by mutations in the HEXA, HEXB, or GM2A genes, leading to defective β-hexosaminidase enzyme activity. This results in the accumulation of GM2 ganglioside in neurons, causing progressive neurodegeneration. The most common forms include Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70913
Although rare, GM2 gangliosidosis represents a critical unmet need…
GM2 Gangliosidosis Market Set to Advance Through 2034, Fueled by Gene Therapy In …
GM2 Gangliosidosis refers to a group of rare, inherited lysosomal storage disorders-including Tay-Sachs disease, Sandhoff disease, and GM2 activator deficiency-caused by mutations that impair the breakdown of GM2 gangliosides in nerve cells. These disorders are characterized by progressive neurodegeneration, muscle weakness, motor impairment, seizures, and early mortality, especially in infantile-onset forms. The most common types, Tay-Sachs and Sandhoff disease, result from mutations in the HEXA and HEXB genes, respectively.
DelveInsight's report,…
GM2 Gangliosidosis Pipeline Overview: 8+ Innovative Therapies Driving Hope in Ra …
The therapeutic landscape for GM2 gangliosidosis-an ultra-rare, inherited lysosomal storage disorder encompassing Tay-Sachs and Sandhoff diseases-is witnessing growing innovation, with the pipeline evolving toward more disease-modifying and potentially curative therapies. GM2 gangliosidosis is caused by mutations affecting β-hexosaminidase A and/or B enzymes, resulting in the toxic accumulation of GM2 gangliosides in neurons, which leads to progressive neurodegeneration. Despite the severity of this disease, current management remains largely supportive, highlighting an…
GM2 Gangliosidosis Market is Predicted to Exhibit Remarkable Growth During the F …
DelveInsight's "GM2 Gangliosidosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the GM2 Gangliosidosis, historical and forecasted epidemiology as well as the GM2 Gangliosidosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the GM2 Gangliosidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GM2 Gangliosidosis Market Forecast
https://www.delveinsight.com/sample-request/gm2-gangliosidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
GM2 Gangliosidosis Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging …
GM2 Gangliosidosis pipeline constitutes 8+ key companies continuously working towards developing 8+ GM2 Gangliosidosis treatment therapies, analyzes DelveInsight
GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay-Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic…
